Sells antibody-based calf scours preventives and on-farm milk tests to dairy and beef producers.
10-K for FY2025, filed Mar 30, 2026ImmuCell Corporation, founded in 1982 and a SEC-registered public company since 1987, is an animal health biologics company focused on the…View ↗
The First Defense® product line is manufactured from hyperimmunized bovine colostrum using proprietary vaccination and milk protein…View ↗
We also offer a California Mastitis Test (CMT) that is used as a quick on-farm diagnostic to determine which quarter of the udder is…View ↗
Dairy and beef producers are reached through distributors; ImmuCell sells products to distributors and invoices when products ship, with customers paying against those invoices.
10-K for FY2025, filed Mar 30, 2026
10-K for FY2025, filed Mar 30, 2026
FY2025 revenue by reportable segment ↗$27.6M
10-K for FY2025, filed Mar 30, 2026
$27.6M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Corporate Segment, Scours
Sold outright
10-K for FY2025, filed Mar 30, 2026 |
99% |
Corporate Segment, Scours, FY2025
$27.4M Sources
|
Sold outright |
|
Corporate Segment, Mastitis
Sold outright
|
0.7% |
Corporate Segment, Mastitis, FY2025
$196.4K Sources
|
Sold outright |
The company promotes its products to veterinarians and dairy and beef producers, then sells mainly through animal-health distributors, which supply veterinary clinics, fleet stores and farms.
10-K for FY2025, filed Mar 30, 2026
Not on paper. It lost $1M in FY2025, but brought in more cash than it spent: $1.2M of free cash flow.
10-Q for Q3 FY2026, filed Nov 12, 2026
$952.5KView ↗
10-Q for Q3 FY2026, filed Nov 12, 2026
Open tableView ↗
Re-Tain's role
The older report described completing Re-Tain's manufacturing work to pursue FDA approval alongside First Defense. The latest report says the company has stopped pursuing in-house manufacturing, redirected related facilities to First Defense, and may seek a licensee or partner for Re-Tain.
10-K for FY2022, filed Mar 29, 2023 10-K for FY2025, filed Mar 30, 2026During 2000, we began the development of Re-Tain®, our purified Nisin treatment for subclinical mastitis in lactating dairy cows. No sales…View ↗
Competes with Zoetis, Elanco, Merck, Boehringer Ingelheim, and CEVA
10-K for FY2025, filed Mar 30, 2026The Company operates within a calf health market that includes vaccine manufacturers and nutritional supplement providers. Primary…View ↗
Loading...